P1.03-01 Polymorphisms in Glycolysis-Related Genes Are Associated with Clinical Outcomes of Paclitaxel-Cisplatin Chemotherapy in NSCLC

Abstract

Conclusion:This comprehensive SLR indicates that uncommon mutations may comprise a clinically significant proportion of the EGFR mutations occurring in NSCLC worldwide. As there are apparent disparities in TKI-sensitivity between some of the most frequently reported uncommon mutations, assessment and reporting of outcomes by specific mutation type will prove invaluable in identifying the most appropriate treatment strategy in each case.